Introduction
In mammalian cells mRNA translation is regulated under a wide variety of conditions (Mathews et al., 1996) . A number of the molecular mechanisms for regulating mRNA translation involve changes in the states of phosphorylation of proteins involved in this process, such as initiation and elongation factors or ribosomal proteins (Kleijn et al., 1998; Proud and Denton, 1997) . Considerable eort has been devoted to elucidating the signalling pathways which link the control of these proteins to external stimuli, e.g., to cell surface receptors. One such signalling pathway involves a protein termed the`mammalian target of rapamycin', mTOR, whose function is inhibited by the macrolide immunosuppressant drug rapamycin (Thomas and Hall, 1998; Dennis et al., 1999) . mTOR regulates events involved in the control of the initiation phase of translation, as demonstrated by the ability of rapamycin to block their regulation. These include (i) p70 S6 kinase (the 70 kDa protein kinase which phosphorylates ribosomal protein S6) and (ii) eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) which inhibits the cap-binding protein eIF4E by sequestering it.
p70 S6 kinase and the phosphorylation of S6 are believed to be important in regulating the translation of a set of mRNAs which encode ribosomal proteins and translation elongation factors. All of these mRNAs possess a sequence of pyrimidines at their extreme 5'-end and are therefore termed TOP mRNAs (`tract of pyrimidines') (Meyuhas et al., 1996) . Their translation is inecient in serum-starved cells but is enhanced by addition of serum and this eect is blocked by rapamycin, demonstrating a dependence on mTOR. The key role played by this kinase in cell growth and proliferation is highlighted by the observation that injection of neutralizing antisera to p70 S6 kinase into mouse ®broblasts blocks their entry into Sphase (Lane et al., 1993) . eIF4E binds to the 5'-cap (7-methylguanosine) of eukaryotic mRNAs and also binds to eIF4G, à scaolding protein' required to recruit eIF4A to the 5'-end of the mRNA to form the eIF4F complex (Gingras et al., 1999) . eIF4A is an RNA helicase that can`unwind' regions of self-complementary secondary structure in the 5'-leader region of the mRNA. Such regions inhibit mRNA translation (probably by impeding ribosomal scanning) and are found in many mRNAs encoding growth regulatory proteins such as growth factors and transcription factors. The function of the cap-binding protein 4E can be inhibited by binding to 4E-BPs (reviewed by Lawrence and Abraham, 1997) , and the best-studied 4E-BP is 4E-BP1. It undergoes phosphorylation in response to many agents which activate translation, e.g., insulin and growth factors (Gingras et al., 1999) , and this leads to its dissociation from eIF4E, making eIF4E available to bind to eIF4G and for assembly of eIF4F complexes. The phosphorylation and dissociation of 4E-BP1 is blocked by rapamycin, showing that it is also downstream of mTOR. The availability of eIF4E plays an important role in controlling cell proliferation: forced over-expression of eIF4E in immortalized cell lines results in malignant transformation (Rousseau et al., 1996b; Lazaris-Karatzas et al., 1990; De Benedetti et al., 1994) while overexpression of 4E-BP1 (or 4E-BP2) reversed the phenotype of cells transformed by overexpression of eIF4E or other manipulations (Rousseau et al., 1996a) . It is thought that overexpression of eIF4E enhances the translation of factors involved in cell growth, and thus transformation, probably by increasing the amount of eIF4F complexes available. Many such mRNAs have 5'-leader regions which are rich in secondary structure, which makes them highly dependent on the abundancy of the eIF4F complex needed for unimpeded ribosomal scanning (Flynn and Proud, 1996) . 4E-BP1 and eIF4E are regulated under a variety of stress conditions (Feigenblum and Schneider, 1996; Scheper et al., 1997; Vries et al., 1997; Wang et al., 1998b) .
Cellular stress caused by DNA damage can elicit a complex array of events, which results in inhibition of cell proliferation and the engagement of processes to repair the DNA damage. Fibroblasts treated with DNA damaging agents have been shown to exhibit an accumulation of nuclear p53 protein and its activation (Fritsche et al., 1993) . Activation of p53 leads to cell growth arrest at the G 1 /S boundary (Kuerbitz et al., 1992; Kastan et al., 1991) . Low concentrations of DNA damaging agents caused such a cell cycle arrest while higher concentrations also resulted in a loss of cell viability (Qu et al., 1999) . Cells with extensive DNA damage may enter a series of events which results in programmed cell death (apoptosis) (Clarke et al., 1993; Lowe et al., 1993) , which generally involves caspase activation (Sun et al., 1999) thereby preventing the proliferation of genetically damaged cells (Lane, 1992) . Although a good deal of research has focused on the mechanisms by which DNA damage results in cell cycle arrest, very little is known of the impact of DNA damage on mRNA translation, which is a key process for cell growth and proliferation. Here we demonstrate that three dierent agents that cause DNA damage in distinct ways lead to the inactivation of p70 S6 kinase (due to its dephosphorylation) and of eIF4E (due to increased association with 4E-BP1, which also undergoes dephosphorylation). These events precede by several hours the entry of the cells into apoptosis and are independent of caspase activation. Since p70 S6 kinase and 4E-BP1 both lie downstream of mTOR, our data imply that DNA-damaging agents impair signalling through the mTOR pathway.
Results

Etoposide induces apoptosis in Swiss 3T3 cells
We initially studied the eects of etoposide, a topoisomerase II inhibitor, that causes DNA damage through increased torsional strain (Tronov et al., 1999) . To assess whether etoposide induces apoptosis in Swiss 3T3 cells, and at what time, we performed two types of analysis. Firstly, cells were stained with propidium iodide and then analysed on a¯uorescence activated cell sorter (FACS analysis) (Figure 1a) . Loss of DNA is a characteristic of cells undergoing apoptosis and these cells can be distinguished from the normal population of cells using FACS analysis. The area of the peak labelled subG 0 /G 1 represents this apoptotic population. After 20 h, etoposide had induced apoptosis in approximately one quarter of the cell population (27.8%+7.5). Induction of apoptosis was con®rmed using a colorimetric assay for caspase-3 activity (Figure 1b ). Up to 12 h of etoposide treatment, no signi®cant activation was observed. By 18 h, a b Figure 1 Etoposide treatment induces apoptosis in Swiss 3T3 cells. (a) Swiss 3T3 cells were treated, as indicated, and subjected to FACS analysis as described in Materials and methods. The apoptotic population of cells is represented by the peak of lower DNA content (n51) labelled subG 0 /G 1 , while diploid cells (n=1) are labelled G 0 /G 1 , and cells that have replicating DNA or are tetraploid are labelled S/G 2 . The per cent mortality is the per cent of cells in the subG 0 /G 1 peak of etoposide treated cells minus the % of cells in the sub G 0 /G 1 fraction in the DMSO control. (b) Swiss 3T3 cells were treated as indicated and caspase-3 activity was determined as described in Materials and methods, (*=P50.005 versus appropriate DMSO control) substantial caspase-3 activity was detected and the activity continued to rise up to 32 h when compared to the control (DMSO-treated) cells, in which no activation was observed. As expected, treatment of cells with Z-VAD.FMK (a broad-spectrum caspase inhibitor) blocked the ability of etoposide to induce caspase-3 activation.
Effects of etoposide on downstream targets of mTOR signalling
The mTOR signalling pathway plays a key role in regulating mRNA translation, cell growth and cell cycle progression (reviewed in Thomas and Hall, 1998) . In order to assess whether DNA damage (and speci®cally etoposide) aected this pathway, we assessed its eect on two well-characterized downstream components of mTOR signalling, p70 S6 kinase and 4E-BP1. p70 S6 kinase activity was measured after immunoprecipitation from extracts of Swiss 3T3 cells treated with etoposide or DMSO alone for various times. After 8 h of etoposide treatment, p70 S6 kinase activity was signi®cantly lower when compared to the DMSO controls and its activity decreased further at later times up to 18 h ( Figure 2a ). As expected, rapamycin (100 nM), caused a substantial inhibition of p70 S6 kinase activity even at the earliest time point. The activity of p70 S6 kinase is regulated by phosphorylation, more highly phosphorylated forms being more active. Such forms exhibit reduced mobility on SDS ± PAGE. p70 S6 kinase from etoposide-treated cells showed a pronounced shift to the more rapidly migrating, less phosphorylated forms (Figure 2b) , consistent with the observed changes in activity. As expected, rapamycin also caused a substantial shift to the lowest band by 1 h of treatment (data not shown).
4E-BP1 is also regulated by phosphorylation: the less phosphorylated forms which bind to and inhibit initiation factor eIF4E show a higher mobility on SDS ± PAGE. Figure 2c shows that 4E-BP1 from Swiss 3T3 cells can be resolved into three main forms on SDS ± PAGE. In cells treated with etoposide, there is a marked dephosphorylation of 4E-BP1 when compared to the DMSO control. About 50% of the 4E-BP1 runs as the b isoform by 8 h and much of the protein is in the a form at 32 h. In cells incubated with DMSO, 4E-BP1 was in the most highly phosphorylated g form at early time-points but there was a gradual shift towards increasing proportions of the b species. This probably re¯ects an increase in con¯uency of the cells. Thus, etoposide treatment causes the net dephosphorylation of 4E-BP1, as described above for p70 S6 kinase. Analysis of extracts from rapamycin-treated cells showed, as expected, that most of the 4E-BP1 was in the a isoform at 4 h. At later times, there was a slight, shift back towards the more phosphorylated forms of 4E-BP1 which might re¯ect a loss of rapamycin's ability to inhibit mTOR over extended time periods.
In order to establish whether etoposide aects 4E-BP1 phosphorylation in other cell-types, we analysed the eect of this agent in RAT-1 cells (Figure 2d ). After 12 h of etoposide treatment the majority of 4E-BP1 migrated as the a isoform and the proportion of this isoform increased over time. The g isoform is more abundant in the DMSO control over the whole time course, again showing that etoposide treatment causes dephosphorylation of 4E-BP1. In both cell types a faster-migrating band (labelled * in Figure 2c ,d) was observed and this will be discussed in more detail below.
The less phosphorylated forms of 4E-BP1 are known to bind to eIF4E (Gingras et al., 1999) . Figure 2e shows that treatment with either rapamycin or etoposide caused a marked increase in the amount of 4E-BP1 associated with eIF4E. It should be noted that the ratio of 4E-BP1 : eIF4E is the important parameter here, rather than the absolute amount of 4E-BP1 observed, and that the amount of eIF4E continues to increase over time with all treatments. Ratios of the signals for the various proteins were determined by densitometric analysis and appear below the relevant panels in Figure 2e . Increased binding of 4E-BP1 to eIF4E was observed as early as 8 h after etoposide treatment. This is consistent with the observation that a proportion of the total 4E-BP1 had shifted to the less phosphorylated b-species by this time (Figure 2c ). At later times (12, 18 h), when 4E-BP1 became less phosphorylated, there was a corresponding further increase in the amount of this protein bound to eIF4E. In the control cells, the binding of 4E-BP1 to eIF4E also rose at later times (Figure 2e ), re¯ecting the dephosphorylation of 4E-BP1 ( Figure 2c ). Rapamycin treatment, as expected, caused an increase in 4E-BP1 binding to eIF4E (Figure 2e ). The binding of 4E-BP1 to eIF4E is mutually exclusive with respect to the binding of eIF4G 1 to eIF4E (Mader et al., 1995) . We therefore studied the amount of eIF4G 1 associated with the eIF4E. The signal for eIF4G 1 associated with eIF4E remained constant in the DMSO control cells, but, allowing for the increased amount of eIF4E present at 18 h, there was actually a small decline in the amount of eIF4G 1 relative to eIF4E (Figure 2e ). In contrast, a much greater decrease in eIF4G 1 binding was observed when cells were treated with etoposide for 8 h or more, which coincided with the increases association of 4E-BP1 with eIF4E. The rapamycin treatment also caused a substantial decrease in binding of eIF4G 1 to eIF4E when compared to the DMSO control at all time points although there was a partial recovery in eIF4G 1 binding at later times, consistent with the small increase in 4E-BP1 phosphorylation mentioned above. Increased binding of 4E-PB1 to eIF4E and the corresponding decrease in eIF4G 1 binding reduce the amount of the eIF4F complexes which are required for cap-dependent translation initiation.
As mentioned above, after longer times of etoposide treatment of both Swiss 3T3 and RAT-1 cells, analysis of 4E-BP1 revealed a more rapidly migrating band (marked * Figure 2c ,d). Since caspases have become activated at these times (Figure 1b) , it seemed possible that this might represent a degradation product of 4E-BP1 generated by caspase action. To test this, Swiss 3T3 cells were incubated with etoposide in the presence or absence of Z-VAD.FMK. Figure 1b shows that Z-VAD.FMK completely prevented caspase activation in Swiss 3T3 cells. It also prevented the appearance of the rapidly migrating species recognized by anti-4E-BP1 antiserum. This rapidly-migrating protein was bound to eIF4E after 18 h etoposide-treatment (Figure 2e ), suggesting that it is indeed a cleavage product of 4E-BP1, which still possesses the eIF4E-binding motif, and whose appearance is dependent upon caspase activity. Our antiserum recognises an epitope at the extreme Cterminus of 4E-BP1: based on the observed mobility of the fragment on SDS ± PAGE, the cleavage must presumably be occurring towards the N-terminus of the protein. Z-VAD.FMK also substantially blocked the cleavage of 4E-BP1 in RAT-1 cells (Figure 2d ). Z-VAD.FMK did not prevent the dephosphorylation of 4E-BP1 in either Swiss 3T3 or RAT-1 cells (Figure 2c, d) . This observation, and the timing of 4E-BP1 dephosphorylation, support the notion that the dephosphorylation of 4E-BP1 is not a consequence of events associated with caspase activation but the result of other alterations in intracellular signalling that precede the onset of apoptosis. Z-VAD.FMK also failed to prevent the inactivation of p70 S6 kinase ( Figure 2a ). This event is thus also independent of caspase activation and the onset of apoptosis. eIF4G 1 has previously been shown to be degraded in cells undergoing apoptosis (Marissen and Lloyd, 1998; Clemens et al., 1998) and this requires caspase activity/ activation (Marissen and Lloyd, 1998; Bushell et al., 1999) . We therefore analysed the total level of eIF4G 1 in ) were used in the in vitro p70 S6 kinase activity assay as described in Materials and methods. The activity of p70 S6 kinase in the 4 h DMSO control was set at 100%, (*=P50.05, **=P50.005, versus appropriate DMSO control). (b) Samples of extract (20 mg of protein) from cells treated with etoposide (100 mM) or DMSO, were analysed by SDS ± PAGE and Western blotting as described under Materials and methods. The arrows indicate the dierent phosphorylated forms of p70 S6 kinase where the top one (PP) represents highly phosphorylated species (active kinase), and the bottom one represents less phosphorylated species (inactive or less active kinase). (c) Swiss 3T3 cells were treated as indicated (etoposide, 100 mM; rapamycin, 100 nM) and harvested at the times stated. Where present, Z-VAD.FMK was used at 20 mM. Samples of extract (30 mg of protein) were subjected to SDS ± PAGE and 4E-BP1 was detected by Western blotting. The a, b and g isoforms of 4E-BP1 are indicated by the arrows where the g species represents the most highly phosphorylated form of 4E-BP1 and the a species the least phosphorylated form of 4E-BP1. The * species probably represents a cleavage product of 4E-BP1 (see text). (d) RAT-1 cells were treated with etoposide, DMSO and/or Z-VAD.FMK and analysed as described in panel C. (e) Samples of Swiss 3T3 cell extract (500 mg of protein) were subjected to anity chromatography on m 7 GTP-Sepharose as described in Materials and methods. The amounts of eIF4G 1 (4G1), eIF4E (4E) and 4E-BP1 were assessed by SDS ± PAGE and Western blotting and quanti®ed by densitometry (NIH Image v. 1.61). Numbers below the panel indicate the ratios of the signals for eIF4G1 relative to eIF4E (4G1/4E) and 4E-BP1 to eIF4E (4EBP1/4E), respectively. They do not represent molar ratios. (f) The total level of eIF4G1 (indicated by`4G1') was determined by subjecting 20 mg of cell extract from Swiss 3T3 cells treated with DMSO or etoposide (100 mM), for the indicated times, to SDS ± PAGE and Western blotting as previously described control and etoposide-treated cells. We detected no change in the level of eIF4G 1 up to 18 h of etoposide treatment but a marked decrease was seen by 36 h (Figure 2f ). This indicates that the degradation of eIF4G 1 induced by etoposide treatment is a relatively late event and occurs many hours after the initial dissociation of the eIF4F complex. The caspase inhibitor Z-VAD.FMK failed to prevent the etoposide-induced loss of eIF4G 1 bound to eIF4E (data not shown). We have clearly shown that there was no signi®cant loss of total eIF4G 1 at these times (eIF4G 1 degradation appears to occur after 18 h of etoposide treatment) and also that etoposide treatment in the presence of Z-VAD.FMK still resulted in the dephosphorylation of 4E-BP1 (Figure 2c ). This clearly demonstrates that the reduced binding of eIF4G 1 is not a consequence of the caspase-mediated degradation of this polypeptide.
Impairment of signalling during apoptosis
The data described above suggest that DNA-damaging agents might inhibit mTOR-linked signalling. To assess whether DNA-damaging agents interfere in a dominant fashion with mTOR signalling, cells which had been treated with etoposide for 11.5 h (pre-apoptotic cells) or 24 h (apoptotic, as judged by caspase activation and FACS analysis, described above) were stimulated acutely with insulin. Insulin brought about the phosphorylation of 4E-BP1 (Figure 3a) and activation of p70 S6 kinase (Figure 3b ) to similar extents in control (DMSO-treated) cells and in cells treated for 11.5 h with etoposide (preapoptotic cells). In contrast, after 24 h of etoposide treatment, the ability of insulin to induce both eects was severely reduced relative to either control (Figure 3b,c) . Thus, in pre-apoptotic cells, signalling through mTOR is inhibited in response to etoposide but this can be overcome by insulin stimulation. In cells undergoing apoptosis, this inhibition of mTOR signalling can no longer be completely overcome by insulin.
Effects of other DNA-damaging agents on mTOR-linked signalling
In order to establish whether impairment of mTORlinked signalling is a general response to DNA damage, or an eect restricted to etoposide, we studied two other antitumour agents that also cause DNA damage but by dierent mechanisms. These were mitomycin-C and cis-platinum(II)diammine dichloride (cisplatin), which both cause DNA damage by the formation of bulky adducts (Schweizer et al., 1999; Palom et al., 1998) . Such DNA lesions elicit a DNA repair response and cell cycle arrest. Both agents caused substantial dephosphorylation of 4E-BP1 by 12 h of treatment compared to the DMSO control (Figure 4a) . By 24 h of treatment, the cleavage product of 4E-BP1 observed in etoposide-treated cells was also seen in those treated with mitomycin-C or cisplatin (indicated by * in Figure  4a ). When caspase-3 activity was monitored, it was clear that no caspase activation occurred at 12 h (at which time dephosphorylation of 4E-BP1 was already apparent) but there was substantial caspase-3 activation by 24 h, when the cleavage product was observed (Figure 4b) . Each of these agents also brought about the inactivation of p70 S6 kinase (Figure 4c ), as observed for etoposide. Again, the eects of rapamycin (which inhibits mTOR directly) were more rapid, indicating that DNA damaging agents operate via dierent mechanisms, probably indirectly.
Rapamycin delays etoposide-induced caspase activation
The observation that inhibition of mTOR-linked signalling is a common eect of DNA-damaging agents a b c Figure 3 DNA damage reversibly impairs insulin signalling in pre-apoptotic cells but irreversibly in apoptotic cells. (a) Swiss 3T3 cells were treated with DMSO or etoposide (Et, 100 mM) in the presence of serum, where indicated, for 11.5 h (pre-apoptotic cells) and then stimulated with insulin (100 nM) for 15, 30 or 60 min, as indicated. The samples were subjected to SDS ± PAGE and Western blotting as before to analyse 4E-BP1 isoforms which are indicated as described for Figure 2c. (b) Swiss 3T3 cells were treated with DMSO or etoposide (100 mM) for 12 or 24 h. At 24 h (apoptotic cells) the cells were also stimulated with insulin (100 nM) for 15, 30 or 60 min. These samples were also analysed for total 4E-BP1 as before and the dierent forms of 4E-BP1 are indicated as described for Figure 2c . (c) Swiss 3T3 cells were treated with DMSO or etoposide (Et, 100 mM) for 11.5 h or 24 h and then stimulated with insulin (100 nM) for 15 min. Assays for p70 S6 kinase were carried out as before on these cell extracts. The activity of the samples from cells treated with DMSO for 11.5 h was set at 100% (*=P50.005 versus appropriate DMSO control) raises the question of its possible role in the eects of these agents. Rapamycin, a potent inhibitor of mTOR, does not by itself induce apoptosis in Swiss 3T3 cells: for example it does not elicit caspase-3 activation ( Figure 5 ). It also failed to enhance the eect of etoposide on caspase activity. These data show that inhibition of mTOR function alone is not sucient to induce apoptosis in these cells. However, treatment of the cells with rapamycin, prior to addition of etoposide (in the continued presence of rapamycin), resulted in a delay in caspase-3 activation. Caspase-3 activity was signi®cantly lower in the cells pretreated with rapamycin compared with cells treated with etoposide alone (Figure 5 ).
Etoposide treatment inhibits protein synthesis
Both p70 S6 kinase and 4E-BP1 are involved in the regulation of mRNA translation and their inactivation in response to DNA-damaging agents is expected to contribute to a reduction in protein synthesis rates. We studied the eect of etoposide on total protein synthesis by measuring the rate of incorporation of [ 35 S]methionine into protein in control and etoposidetreated cells. The data clearly show that etoposide caused a 25% inhibition of protein synthesis by 8 h, compared to the DMSO control, and the magnitude of this inhibition increased up to 75% at 18 h ( Figure 6 ). Thus etoposide clearly causes inhibition of protein synthesis. This inhibition was not prevented by treatment of the cells with Z-VAD.FMK showing that it is independent of caspase activation. However, the magnitude of the decrease in response to etoposide was greater than that caused by rapamycin, which, like etoposide, causes inhibition of p70 S6 kinase and dephosphorylation of 4E-BP1. These data are in line with those for other cells, where treatment of serum-fed cells with rapamycin generally only causes a modest inhibition of total protein synthesis, especially at early times (see, e.g., (Beretta et al., 1996; Morley et al., 1998) ). It thus seemed likely that etoposide interfered with other steps in mRNA translation in addition to those regulated through mTOR, and we therefore extended our analysis to include two proteins which are known to play key roles in regulating overall protein synthesis, eIF2 and eIF2B. Morley et al. (1998) have previously shown that etoposide inhibits protein synthesis in Jurkat cells and that this inhibition was not aected by pretreatment of the cells with Z-VAD.FMK.
Effect of etoposide on other proteins that regulate translation
The phosphorylation of the a-subunit of eIF2 is known to regulate overall protein synthesis under a wide variety of stress conditions, by inhibiting the activity of the guanine nucleotide-exchange factor eIF2B, and is a b c Figure 4 Dephosphorylation and formation of a cleavage product of 4E-BP1 by DNA-damaging agents. (a) Swiss 3T3 cells were treated as indicated with etoposide (100 mM), cisplatin (50 mM), or mitomycin-C (10 mg/ml) for 12 and 24 h. Total 4E-BP1 was analysed by SDS ± PAGE and Western blotting to assess the levels of the phosphorylated forms and the cleaved species (see Figure 2c for labelling of species of 4E-BP1). (b) Extracts from Swiss 3T3 cells which had been treated under the same conditions as in (a) were analysed for caspase-3 activity as described in Materials and methods. (c) p70 S6 kinase assays were carried out on 150 mg of cell extract protein from Swiss 3T3 cells treated as described in (a). The activity of the 4 h DMSO control sample was set at 100%. (*=P50.05, **=P50.005 versus appropriate DMSO control) implicated in apoptosis (Srivastava et al., 1998; Jagus et al., 1999; Clemens, 1996) . To ascertain whether etoposide aected the phosphorylation of eIF2a we used isoelectric focusing followed by immunoblotting to assess the proportion of eIF2a which was in its phosphorylated form at each time. This analysis revealed that most of the eIF2a remained in its nonphosphorylated form at all times (Figure 7, upper panel) and that the proportion in the phospho-form was almost undetectable (a trace was observed but is barely visible in Figure 7, upper panel) . In order to visualize the phosphorylated form of eIF2a directly, we reprobed the membrane with an antibody that speci®cally recognizes the protein when the regulatory site, Ser51, is phosphorylated (DeGracia et al., 1997) ( Figure 7, lower panel) . These data clearly showed that the level of eIF2a phosphorylation did not increase upon etoposide treatment. The reduction in protein synthesis at these times (up to 12 h etoposide treatment) does not appear to be due to increased phosphorylation of eIF2a. It thus seems likely that changes in the activities of other components of the translational machinery are probably involved.
A further way of regulating the activity of eIF2B is through changes in the phosphorylation of its esubunit: phosphorylation at a conserved serine (Ser540 in the rabbit protein (Welsh et al., 1998) by glycogen synthase kinase-3 inhibits its activity. To check whether etoposide aected phosphorylation at this regulatory site we made use of an antibody which detects eIF2Be only when this site is phosphorylated (Welsh et al., 1998) . However, no dierence in the signal obtained using this antiserum in Western blots was observed in cells treated with etoposide, or in control cells over the time course studied (data not shown).
Discussion
The data presented here show that treatment of cells with any of three DNA-damaging agents that are commonly used in chemotherapy results in the Figure 7 Etoposide treatment does not induce phosphorylation of eIF2a. eIF2 was partially puri®ed from Swiss 3T3 cells treated with DMSO or etoposide (Et, 100 mM), as indicated. Samples were subjected to isoelectric focusing (IEF) and Western blotting using anti-eIF2a antibodies (upper panel, labelled anti-eIF2a) or anti-eIF2a(P) antiserum (lower panel, labelled anti-eIF2a(P)) to determine the levels of eIF2a phosphorylation as previously described in Materials and methods. eIF2a which had been partially puri®ed from extract of Swiss cells pretreated with DMSO for 4 h was incubated with HRI as described in Materials and methods, prior to isoelectric focusing, as a positive control of eIF2a phosphorylation. The arrows in the upper panel indicate dierent phosphorylated species of eIF2a, where the top one (eIF2a(P)) represents phosphorylated eIF2a. The species running above the phosphorylated form of eIF2a in the ®rst lane of the lower panel is probably a carbamylation adduct of eIF2a; such adducts are often seen in IEF analyses Figure 5 Rapamycin treatment delays caspase-3 activation in etoposide-treated cells. Swiss 3T3 cells were treated with DMSO or etoposide (Et, 100 mM) in the presence or absence of rapamycin (Rap, 100 nM) or with rapamycin alone. Where indicated, the cells were pre-treated with rapamycin (preRap, 100 nM) for 12 h before addition of etoposide or a second dose of rapamycin. The cells were harvested at the times stated and a caspase-3 assay was carried out on the lysates, as described in Materials and methods, (*=P50.05, **=P50.005 versus appropriate Et control) Figure 6 Etoposide treatment inhibits total protein synthesis in a caspase independent manner. Swiss 3T3 cells were treated with DMSO, etoposide in the presence or absence of Z-VAD.FMK, or rapamycin for the times indicated. At the end of this period, the cells were incubated with [ 35 S]methionine for a further 20 min before harvesting. The incorporation of radiolabel into cellular protein was quanti®ed as described in Materials and methods. All samples were equilibrated for protein levels and standardized against the DMSO control (set at 100%) for each time point (*=P50.05, **=P50.005 versus appropriate DMSO control) inactivation of two key regulatory components of the translational machinery. Firstly, eIF4E becomes inhibited due to an increased association with the dephosphorylated species of the inhibitory binding protein, 4E-BP1. This increase in association prevents eIF4E from binding to eIF4G to form eIF4F complexes (Gingras et al., 1999) , and we observe dissociation of eIF4F complexes in etoposide-treated cells (Figure 2e ). Cisplatin and mitomycin-C also caused the dephosphorylation of 4E-BP1: they are therefore also likely to cause the dissociation of eIF4F complexes. Secondly, these agents also bring about the dephosphorylation and inactivation of p70 S6 kinase. The phosphorylation of both 4E-BP1 and p70 S6 kinase is regulated through signalling pathways linked to mTOR, which is inhibited by rapamycin. Treatment of cells with this drug decreased the activity and phosphorylation of p70 S6 kinase (Figures 2a and 4c) , the phosphorylation state of 4E-BP1 (Figures 2c,d and  4a ) and the association of eIF4G 1 with eIF4E ( Figure  2e ), which resembles the eects of etoposide, although rapamycin acts more rapidly. Taken together, these data suggest that treatment with any of these three DNA-damaging agents causes an impairment of signalling through mTOR or of signalling pathways which are linked to mTOR.
Our data reveal that the DNA-damaging agent, etoposide, caused a marked inhibition of overall protein synthesis (Figure 6 ) that increased over time (from 25 ± 75% inhibition of the level in control cells). Given that rapamycin, which also causes inactivation of p70 S6 kinase and eIF4E, caused a modest decrease in the rate of translation, the eect of etoposide is presumably due, at least in part, to the decreases in p70 S6 kinase activity and eIF4E function brought about by this agent. However, the degree of inhibition was larger than that observed in cells treated with rapamycin indicating that additional eects contribute to the shut-o of protein synthesis in cells suering DNA damage. It has been suggested that phosphorylation of eIF2a may be important during virus-induced apoptosis (Jagus et al., 1999; Srivastava et al., 1998) . Apoptosis can be triggered by the interferon-induced protein kinase PKR that phosphorylates eIF2a and thus inhibits protein synthesis at the level of initiation (Balachandran et al., 1998; Donze et al., 1999; Gil et al., 1999; Takizawa et al., 1999; Yeung et al., 1996) . However, our observation that the phosphorylation of eIF2a was not increased in cells treated with the DNAdamaging agent, etoposide, indicates that PKR is not involved here and that additional eects must therefore contribute to the shut-down of protein synthesis observed in response to etoposide in pre-apoptotic cells.
Both p70 S6 kinase and eIF4E are implicated primarily in the regulation of speci®c sets of mRNAs that are involved in cell growth and proliferation. p70 S6 kinase regulates the translation of TOP mRNAs which encode elongation factors and ribosomal proteins (Meyuhas et al., 1996) , while eIF4E function is thought to regulate the translation of transcription factors (e.g., c-myc and c-fos, Clemens and Bommer, 1999) and other proteins involved in cell growth, presumably via the assembly of the eIF4F complex (McWhinney et al., 1998) . This suggests that DNAdamaging agents aect the translational machinery to decrease the synthesis of proteins involved in cell growth and its regulation. It is thought that cells respond to lesser degrees of DNA damage by inhibiting their cell growth and division to allow these cells to repair their damaged DNA. p70 S6 kinase is implicated in cell-cycle progression (Lane et al., 1993) . It is therefore probable that the inhibition of mTOR signalling induced by DNA damaging agents plays a role in inhibiting cell growth to allow recovery from DNA damage.
The eects of DNA-damaging agents on translational regulators precede, by several hours, the entry of the cells into apoptosis, as assessed by two independent criteria, FACS analysis and caspase activation ( Figure  1a,b) . Inhibition of eIF4E and p70 S6 kinase is therefore clearly not a consequence of apoptosis. It also precedes the cleavage of 4E-BP1, which we observed in cells treated with any of the DNAdamaging agents used at later times when caspases are active (Figures 1b, 4c, 5a,b) , and the cleavage of eIF4G 1 (Figure 2f ), which occurs as a consequence of caspase-3 activation in cells which are actively undergoing apoptosis (Clemens et al., 1998; Marissen and Lloyd, 1998; Bushell et al., 1999) . The broad-speci®city caspase inhibitor Z-VAD.FMK did not prevent the inhibition of protein synthesis (Figure 6 ), the inactivation of p70 S6 kinase (Figure 2a) , the dephosphorylation of 4E-BP1 (Figure 2c ) or the dissociation of eIF4E:eIF4F complexes (data not shown), demonstrating that all these eects are independent of caspase activity. These ®ndings, and the timing of these events relative to caspase activation, show that the etoposideinduced shut-o of protein synthesis, inactivation of p70 S6 kinase and eIF4E all precede the onset of apoptosis and are not due to caspase activation.
At later times, when caspases have undergone activation, they do appear to be required for the cleavage of 4E-BP1. While this paper was in preparation, Bushell et al. (2000) reported that a number of translation factors (eIF4B, the p35 component of eIF3, the a-and b-subunits of eIF2, and also 4E-BP1) are cleaved during apoptosis in BJAB or Jurkat cells treated with cycloheximide. Most of these cleavages occur late in apoptosis and were blocked by caspase inhibitors. Satoh et al. (1999) have also found that eIF2a undergoes degradation during apoptosis. All these events appear to be associated with apoptosis, rather than preceding it, which is the case for the changes in p70 S6 kinase, 4E-BP1 and eIF4F which we report here in response to DNA damage.
The observation that the reduction in the rate of protein synthesis in etoposide-treated cells is greater than that in cells treated with rapamycin suggests that the eect of etoposide involves additional events besides the inactivation of p70 S6 kinase and the dephosphorylation of 4E-BP1, although these events presumably contribute to the shut-o of translation caused by etoposide. Our data show that etoposide does not eect the phosphorylation of eIF2a or of eIF2Be (at Ser540) indicating that further, and so far unidenti®ed, eects are also involved in the inhibition of protein synthesis caused by this agent.
Acute treatment with insulin is still able to induce the activation of p70 S6 kinase and the phosphorylation of 4E-BP1 in cells treated for 11.5 h with etoposide, i.e., prior to commencement of apoptosis (Figure 3a) . This shows that, while DNA damage interferes with signalling through mTOR in cells maintained in serum, mTOR is not blocked irreversibly. In contrast, another stressful condition which inhibits mTOR signalling, amino acid withdrawal, does block it irreversibly, as indicated by the inability of insulin to activate, e.g., 4E-BP1 phosphorylation in amino acid-deprived cells (Campbell et al., 1999; Hara et al., 1998; Patti et al., 1998) . This suggests that DNAdamaging agents act on mTOR in a dierent way to impair its function. At later times, when the cells were actually undergoing apoptosis, the ability of insulin to induce these eects was severely impaired suggesting that during apoptosis there is a decline in the mTOR signalling process which is not overcome by extracellular stimuli such as insulin. It is possible that a component involved in mTOR signalling undergoes irreversible inactivation, perhaps by degradation, in apoptotic cells. A possible candidate here is protein kinase B (PKB) which has been implicated in mTOR signalling (Gingras et al., 1998; Scott et al., 1998; NaveÂ et al., 1999) and has recently been shown to be cleaved in apoptotic cells (Rokudai et al., 2000) .
How might DNA damage modulate mTOR signalling? We have been unable to detect a reproducible change in the protein kinase activity of mTOR using an assay based on its ability to phosphorylate 4E-BP1 in vitro (Burnett et al., 1998) . It is unclear whether this assay really re¯ects a physiological activity of mTOR ± its activity against 4E-BP1 is poor and is only evident under non-physiological conditions (high concentrations of Mn 2+ ). In view of these reservations and complications, we have not carried out further analysis of mTOR activity. mTOR is related to several proteins which play key roles in the DNA-damage response, i.e., DNA-PK (DNA-dependent protein kinase), ATM (ataxia talengiectasia mutated) and ATR (ataxia talengiectasia and Rad 3-related), which respond to nuclear signals that activate DNA repair and elicit cell cycle arrest (Hoekstra, 1997) . It is possible that common signalling pathways impinge on mTOR and one or more of these related proteins in response to DNA damage.
Rapamycin has been shown to induce or potentiate apoptosis in various T-lymphocyte-derived cell lines (Shi et al., 1995; Ishizuka et al., 1997) . However, its eects on cell survival vary between cell types. For example, it has been shown to inhibit the onset of didemnin B-induced apoptosis in HL-60 cell lines (Johnson and Lawen, 1999) . In our experiments, rapamycin did not induce apoptosis in Swiss 3T3 cells or exhibit synergy when used together with etoposide ( Figure 5 and data not shown). Instead, pretreatment of cells with rapamycin delayed the onset of caspase-3 activation induced by subsequent treatment with etoposide in the continued presence of rapamycin ( Figure 5 ). Inhibition of mTOR for this time period is expected to inhibit cell growth (indeed, rapamycin signi®cantly inhibits protein synthesis over such time periods, Figure 6 ). By inhibiting cell growth, rapamycin may reduce the sensitivity of the cells to DNA damage, to which proliferating cells are known to be more sensitive (Sullivan et al., 1987) .
Our data show for the ®rst time that treatment of mammalian cells with agents that cause DNA damage results in inhibition of protein synthesis which is associated with inactivation of two proteins that play key roles in regulating mRNA translation. The data imply that DNA damage results in impairment of signalling through mTOR that may contribute to decreases in cell growth and in the translation of mRNAs encoding proteins involved in cellular proliferation.
Materials and methods
Chemicals and biochemicals
All standard laboratory chemicals and cytotoxic chemicals; etoposide, mitomycin-C and cisplatin were purchased from Sigma. Tissue culture reagents were supplied from Gibco, unless otherwise stated. General reagents for SDS gel electrophoresis were obtained from BDH Merck. m 
Cell culture and cytotoxic treatment
Swiss 3T3 and RAT-1 cells, kindly provided by Dr BA Spruce (Dundee), were grown and maintained in Dulbecco's modi®ed Eagle's medium (DMEM) containing 10% (v/v) foetal calf serum. When 70% con¯uent, the cells were treated for various times with cytotoxic drugs dissolved in dimethyl sulphoxide (DMSO) in the presence of 10% (v/v) foetal calf serum, as indicated in the ®gures. The ®nal concentration of DMSO was 0.2% (v/v) for all treatments. The non-adherent cells, after treatment, were pelleted (2500 r.p.m., 5 min, 48C) and washed twice with cold phosphate buered saline (PBS) and then extracted together with the adherent cells in a buer containing 50 mM b-glycerophosphate, pH 7.4; 1 mM EDTA; 1 mM EGTA; 0.5 mM Na 3 VO 4 ; 1 mM benzamidine hydrochloride; 1 mM dithiothreitol; 0.1 mM phenylmethane sulphonyl¯uoride; 1% (v/v) Triton X-100, and 1 mg/ml each of pepstatin, antipain and leupeptin. Protein concentrations were determined by the Bradford method (Bradford, 1976) .
In vitro protein kinase assays p70 S6 kinase was immunoprecipitated using anti-(p70 S6 kinase) antibodies and its activity measured against an S6 peptide substrate, as described previously (Moule et al., 1995) . To assess the phosphorylation state of p70 S6 kinase by its electrophoretic mobility shift, samples of cell extract were resolved on a 10% polyacrylamide gel, transferred to Immobilon membrane and blots were developed with the anti-p70 S6 kinase antiserum, as described earlier. All immunoblots were developed by enhanced chemiluminescence (ECL, Pharmacia Biotech Inc.).
Western blot analysis to determine translation factor phosphorylation and association Anity chromatography on m 7 GTP-Sepharose was used to isolate eIF4E and its associated proteins (e.g., 4E-BP1 or eIF4G) from cell extracts and these were identi®ed by SDS ± PAGE and Western blotting, as described previously (Campbell et al., 1999; Wang et al., 1998a) . Total eIF4G 1 was determined by analysing samples on a 12.5% polyacrylamide gel followed by Western blotting with an anity puri®ed anti eIF4G 1 antiserum that was prepared using an eIF4G 1 aminoterminal derived peptide (CKKEAVGDLLDAFKEAN) as immunogen. The phosphorylation state of 4E-BP1 was assessed by its mobility on SDS ± PAGE as described earlier (Kleijn et al., 1996) . eIF2a phosphorylation was determined by isoelectric focusing and Western blotting on eIF2a partially puri®ed from Swiss 3T3 cells (Welsh and Proud, 1992) using an antibody that speci®cally recognises the phosphorylated form of the protein, anti-(eIF2a(P)) (DeGracia et al., 1997) and a monoclonal mouse derived anti-(eIF2a) antibody, kindly provided by the late Dr E Henshaw. In vitro phosphorylation of eIF2a was carried out using extraction buer supplemented with 0.25 mM MgCl 2 , 12.5 mM ATP, 60 mM NaF and 0.6 mM microcystin using haem-regulated inhibitor (HRI), a kind gift from Dr JJ Chen, for 20 min at 308C.
Assays for protein synthesis
The rates of protein synthesis were assayed in near-con¯uent Swiss 3T3 cells, grown in 24 multiwell plates, by measuring the incorporation of [ Smethionine for 20 min prior to harvesting in extraction buer. The protein concentrations in the extracts were then quanti®ed using the Bradford method (Bradford, 1976) . Aliquots (20 ml) of cell extract were applied to 161 cm squares of 3MM ®lter paper (Whatman) which were then washed three times for 1 min in boiling 5% (w/v) trichloracetic acid containing a trace of cold L-methionine. Filters were rinsed once in ethanol and dried before radioactivity was determined by scintillation counting in Econo¯uor (Packard). Data were normalized to the protein content of each extract.
Assays for apoptosis
The Fluorescence¯ow cytometry analysis was carried out on a Becton Dickinson FACScan using the LYSISII Ver 1.1 Copyright # 1991 programme. Swiss 3T3 cells were ®xed in methanol at 7708C and then incubated with 100 mg/ml RNAase A, and 25 mg/ml propidium iodide; a modi®ed protocol from (Darzynkiewicz, 1994) . Caspase-3 activity were measured using the CaspACE TM System Colorimetric Assay Kit from Promega according to the manufacturer's instructions. In this assay, caspase-3 activity was measured by the speci®c cleavage of a caspase-3 substrate that results in the liberation of product which absorbs at 410 nM, allowing one to quantify the levels of pmol-pNA liberated, using pNA as a standard.
